Passa al contenuto
Merck

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

09415

Sodium 4-aminosalicylate dihydrate

≥97.0% (T)

Sinonimo/i:

4-Amino-2-hydroxybenzoic acid sodium salt, 4-Amino-salicylic acid sodium salt

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
Taglio della confezioneSKUDisponibilitàPrezzo
50 g
Per conoscere la disponibilità, visualizza il carrello
CHF 42.70

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C7H6NNaO3 · 2H2O
Numero CAS:
6018-19-5
Peso molecolare:
211.15
NACRES:
NA.22
PubChem Substance ID:
329748763
UNSPSC Code:
41116107
EC Number:
205-091-2
MDL number:
MFCD00151044
Assay:
≥97.0% (T)
Form:
powder

CHF 42.70

Per conoscere la disponibilità, visualizza il carrello
​
Richiedi un ordine in blocco
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Quality Segment

200

assay

≥97.0% (T)

form

powder

reaction suitability

reaction type: solution phase peptide synthesis

technique(s)

ligand binding assay: suitable

color

white to faintly beige

application(s)

peptide synthesis

SMILES string

O.O.[Na+].Nc1ccc(c(O)c1)C([O-])=O

InChI

1S/C7H7NO3.Na.2H2O/c8-4-1-2-5(7(10)11)6(9)3-4;;;/h1-3,9H,8H2,(H,10,11);;2*1H2/q;+1;;/p-1

InChI key

GMUQJDAYXZXBOT-UHFFFAOYSA-M

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
70862S2679H3766
Sodium 4-aminosalicylate dihydrate ≥97.0% (T)

Sigma-Aldrich

09415

Sodium 4-aminosalicylate dihydrate

4-Amino-1-naphthalenesulfonic acid sodium salt hydrate technical

Sigma-Aldrich

70862

4-Amino-1-naphthalenesulfonic acid sodium salt hydrate

Sodium salicylate 98.0-102.0% anhydrous basis, meets USP testing specifications

Sigma-Aldrich

S2679

Sodium salicylate

Sodium 4-hydroxybenzoate analytical standard

Supelco

H3766

Sodium 4-hydroxybenzoate

assay

≥97.0% (T)

assay

-

assay

98.0-102.0% anhydrous basis

assay

≥98.0% (HPLC)

reaction suitability

reaction type: solution phase peptide synthesis

reaction suitability

-

reaction suitability

-

reaction suitability

-

Quality Level

200

Quality Level

100

Quality Level

200

Quality Level

100

form

powder

form

crystals

form

crystalline

form

-

application(s)

peptide synthesis

application(s)

-

application(s)

pharmaceutical (small molecule)

application(s)

food and beverages

technique(s)

ligand binding assay: suitable

technique(s)

-

technique(s)

-

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0001257115

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Shuichi Yano et al.
BMJ case reports, 2012, doi:10-doi:10 (2012-05-19)
Isoniazid (H) or rifampicin (R) mono-resistant disease can be treated easily and effectively with first-line drugs, while combined H and R resistance (ie, multidrug-resistant tuberculosis (MDRTB)) requires treatment with at least four agents, including a quinolone and an injectable agent.
S M Vesenbeckh et al.
Infection, 40(2), 199-202 (2011-08-13)
para-Aminosalicylic acid (PAS) is commonly used in the treatment of drug-resistant tuberculosis, including multidrug-resistant tuberculosis. Since its first use in the 1940s, hypersensitivity reactions frequently limit its use in clinical practice. Cases of successful desensitization against PAS using orally administered
V E Sagynbaeva et al.
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, (3)(3), 40-46 (2012-07-27)
Detection of IgM and IgG Chlamydia and Mycoplasma pneumoniae indicates an aggravation of intracellular infections, including, possibly, due to immunosuppressive therapy. It is possible that the intracellular infection may mediate the occurrence of certain extraintestinal manifestations of inflammatory bowel disease
Visualizza tutti i documenti correlati

Numero articolo commerciale globale

SKUGTIN
278777-10G04061837836961
09415-50G04061838344724

Questions

Reviews

No rating value

Active Filters